Immunome (IMNM) CEO adds 25,450 shares in $19.67 stock purchase

Filing Impact

(Very High)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Immunome Inc. President and CEO Clay B. Siegall bought 25,450 shares of Common Stock in an open-market purchase. The transaction occurred on March 27, 2026 at a weighted average price of $19.67 per share, within a price range of $19.63 to $19.70.

Following this purchase, his direct holdings increased to 690,704 shares of Immunome Common Stock.

Insider Trade Summary

Net Buyer: 25,450 shares ($500,602)

Net Buy 1 txn

Insider SIEGALL CLAY B

Role President and CEO

Bought 25,450 shs ($501K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	25,450	$19.67	$501K

Holdings After Transaction: Common Stock — 690,704 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Shares purchased: 25,450 shares Weighted average price: $19.67 per share Price range: $19.63–$19.70 per share +1 more

4 metrics

Shares purchased 25,450 shares Open-market purchase on March 27, 2026

Weighted average price $19.67 per share Average purchase price for the reported transaction

Price range $19.63–$19.70 per share Range of individual trade prices within the purchase

Shares owned after transaction 690,704 shares Direct Common Stock holdings following the purchase

Key Terms

open-market purchase, weighted average purchase price, Common Stock, Form 4

4 terms

open-market purchase financial

"transaction_action is described as an open-market purchase of Common Stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average purchase price financial

"The weighted average purchase price for the transaction report was $19.67"

The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.

Common Stock financial

"The security title for the reported transaction is Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"Insider activity is reported in a Form 4 filing with the SEC"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

03/31/2026 - 07:11 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SIEGALL CLAY B

(Last)

(First)

(Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL

WASHINGTON

98011

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/27/2026		P		25,450	A	$19.67⁽¹⁾	690,704	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The weighted average purchase price for the transaction report was $19.67, and the range of prices were between $19.63 and $19.70, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

	/s/ Sandra Stoneman, Attorney-in-Fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Immunome (IMNM) CEO Clay Siegall report in this Form 4 filing?

Clay B. Siegall reported buying 25,450 shares of Immunome Common Stock. The open-market purchase on March 27, 2026, increased his direct holdings to 690,704 shares, reflecting a larger personal stake in the company’s equity.

At what price did the Immunome (IMNM) CEO purchase the 25,450 shares?

The CEO’s purchase had a weighted average price of $19.67 per share. According to the filing, individual trades were executed in a range from $19.63 to $19.70, and detailed trade breakdowns are available upon request to the issuer or SEC staff.

How many Immunome (IMNM) shares does Clay Siegall hold after this transaction?

After the March 27, 2026 purchase, Clay B. Siegall directly holds 690,704 shares. This total reflects his updated Common Stock position as reported in the Form 4 and does not include any derivative securities, which were not listed in this filing.

Was the Immunome (IMNM) CEO’s trade an open-market transaction?

Yes, the Form 4 describes the transaction as an open-market purchase. This means shares were bought on the public market rather than through a grant or option exercise, at prices ranging from $19.63 to $19.70 per share.

Does this Immunome (IMNM) Form 4 include any option exercises or derivative transactions?

No, this Form 4 only reports a non-derivative purchase of Common Stock. The derivativeSummary section is empty, indicating no options, warrants, or other derivative securities were exercised or converted in this specific filing.